SEEL Seelos TherapeuticsWatchlist
About Seelos Therapeutics Company
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersPHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million. Travere Therapeutic
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members
SSNT, MESO and AMPE Among Pre-market Losers
Officer Mehra Raj purchased 75,757 shares of Common Stocks on Dec 1, 2023 at an average price of $1.32 for a total value of $99,999.24.
Seelos Therapeutics (SEEL) announced a 1-for-30 reverse stock split, effective November 28, 2023, to regain compliance with Nasdaq's minimum bid price requirement. Following the split, SEEL's common stock will continue trading on the Nasdaq Capital Market under the symbol "SEEL." The reverse split aims to reduce the number of issued and outstanding shares from approximately 167.7 million to around 5.6 million.
This move is often undertaken by companies to meet exc...